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Abstract
Substance P, thyrotropin-releasing hormone (TRH) and serotonin are putative neurotransmitters
which have been proposed to coexist in some brain neurons Our previous immunocytochemical
and biochemical studies have demonstrated that 85–100% of all serotonin neurons are destroyed
following neonatal 5,7-dihydroxtryptamine (5,7-DHT) treatment In this study, we have
determined the effect of neonatal 5,7-DHT and desipramine (DMI) treatment on the biochemical
content and immunocytochemical localization of substance P and TRH throughout the brain
Interestingly, we have observed that virtually all substance P- and TRH-immunoreactive cells in
the ventral pons-medulla are destroyed by the neurotoxin. However, peptide-containing neurons in
other regions were not affected Additionally, we measured the peptide content and found that
TRH is significantly decreased in the spinal cord (−50%) and pons-medulla (−20%), but not in
other brain regions Substance P content was not significantly altered in any region, even after a
greater than 90% reduction of serotonin These data indicate that the co-localized substance P and
TRH forms a small proportion of the total peptide in brain
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Introduction
Substance P and TRH are neuroactive peptides which have been proposed to co-exist with
serotonin in some neurons of the rat brain8,9,16. Johannson et al 20 have shown that
serotonin immunoreactivity is present in medullary neurons which also contain TRH and/or
substance P. This quantitative immunocytochemical study has indicated that relationships
between these compounds are complex, as demonstrated by the variable populations of
hindbrain serotonergic neurons which contain none, one or both peptides Another approach
to demonstrate co-localization existence consists of the treatment of adult rats with the
selective serotonin neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT) and measurement of
changes in TRH or SP content by radioimmunoassay5,7 12,24,30. These biochemical studies
have generally indicated that substance P and TRH content in the ventral spinal cord
declines concomitantly with a decrease in serotonin content.
In recent reports6,35 we have demonstrated that 5,7-DHT treatment of neonatal rats leads to
permanent destruction of virtually the entire serotonergic neuronal population. Intracisternal
injection of 5,7-DHT into 3-day-old rats leads to the rapid degeneration of 80–98% of
serotonergic neurons throughout the brain Pretreatment with desipramine or pargyline
effectively protects catecholamine neurons from toxic effects of 5,7-DHT In contrast,
previous paradigms for 5,7-DHT-induced lesion of serotonergic neurons have been only
partially effective, since treatment of adult rats leads to pruning of distal terminals without
any apparent proximal damage and loss of cell bodies In this investigation, we applied our
technique for the total destruction of the serotonergic system to determine whether or not
cells containing the putative co-localized peptides TRH and SP are lesioned concurrently




Three-day-old Sprague–Dawley rats (Charles River Breeders, Willmington, MA) received
an intracisternal injection of 50 μg 5,7-DHT, 1 h after desipramine (DMI; 20 mg/kg i.p.).
Animals were treated with capsaicin (50 mg/kg) on day 5 (ref. 19). Control rats received DMI
alone. Some animals sacrificed for immunocytochemistry were pretreated with cholchicine
(100 μg, intraventricularly) 24 h prior to perfusion.
Biochemistry
Substance P content was determined by a modification of the radioimmunoassay as
described by Cuello et al.10, using a monoclonal substance P antibody (clone NCI/34;
Seralabs, Crawley, U.K.) in a non-equilibrium assay. Briefly, tissues were homogenized in
5% trichloroacetic acid, 5 mM ascorbic acid and centrifuged at 24,000 g for 10 min. An
aliquot of the supernatant fraction was extracted 3 times with water-saturated ether to
remove the trichloroacetic acid. A 100 μl aliquot was preincubated with 100 μl antibody
(1:4000) for 3 h and then 10,000 dpm of [125I]Tyr8-substance P was added. After the assay
mixture was incubated overnight with shaking at 4 °C, the antibody bound substance P was
precipitated with an equal volume of 100% saturated ammonium sulfate. The precipitate was
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rinsed with 50% saturated ammonium sulfate and was counted The [125I]Tyr8-substance P
was synthesized by the procedure of Hunter and Greenwood18 and purified on a 20 cm
Sephadex G-25 column equilibrated with 0.1% bovine serum albumin.
TRH content was determined in a similar radioimmunoassay, using an aliquot from the ether
extracted supernatant. The TRH antibody was prepared in rabbits immunized with a TRH-
BSA conjugate formed with bis-diazotised benzidine1. A 100 μl sample was combined with
equal volumes of TRH antisera (1:1000) and 10,000 dpm of [125I]TRH. After incubating
overnight, the antisera-bound TRH was precipitated with saturated ammonium sulfate,
rinsed and counted on a gamma counter.
Serotonin was determined in the initial trichloroacetic acid supernatant by a reverse-phase
high-performance liquid chromatography (HPLC) method which has been described
previously22. Protein concentrations were determined by the method of Lowry et al.25, using
bovine serum albumin as a standard.
Immunocytochemistry
Animals were sacrificed with chloral hydrate (40 mg/kg, i.p.) and prepared for serotonin and
substance P immunostaining by transcardial perfusion with 4% paraformaldehyde, pH 6.8,
followed immediately by 4% paraformaldehyde, pH 10.5 (ref. 3). The brain was processed
through ethanol and toluene for routine embedding in Paraplast plus (Fisher). Following
rehydration, serial 10 μm coronal sections were treated with trypsin (1.2 mg/ml PBS,
Boehringer Mannheim) for 10 min, rinsed extensively and incubated for 48 h at 4 °C with a
monoclonal substance P antibody (1:1000; Seralabs, Crawley, U.K.) or a serotonin antisera
(1:2000). The primary serotonin antiserum and substance P antibody were localized using a
modified ‘ABC’ technique which has been described previously17-34. Since the monoclonal
substance P antibody was a rat IgG, we used biotinylated rabbit anti-rat IGg (1:1000, Vector
Laboratories. Burlingame, CA).
Animals used for TRH and SP immunostaining were anesthetized with chloral hydrate, then
perfused for 5 min with 4% acrolein (Aldrich Chemicals Gold label) in 100 mM phosphate,
pH 7.2 (ref. 23). Forty-micron Vibratome sections were permeabilized with ethanol (50%,
70%, 50% in PBS) and incubated with primary antisera (TRH 1:1500; SP 1:1000) for 48 h at
4 °C. The TRH was visualized using a single bridge peroxidase–antiperoxidase technique36
and substance P was visualized by the ABC method
The specificity of the antisera was determined by liquid-phase absorption with appropriate
ligand for 24 h prior to application onto tissue sections. Serotonin immunoreactivity was
completely blocked by preincubation with 5 μM 6-OH-tetrahydro-β-carboline, a reaction
product of serotonin and formaldehyde. Similarly, the binding of the TRH antiserum and SP
monoclonal antibody was inhibited by 5 μM TRH or SP, respectively.
Results
Biochemistry
In previous investigations we have demonstrated the permanent depletion of serotonin
(>90%) throughout the adult brain following neonatal 5,7-DHT treatment35. In this study we
have measured the depletion of substance P and TRH in order to determine biochemically
the extent of peptide-serotonin co–localization throughout the brain. In adult rats (45 days
old), treated neonatally with 5,7-DHT, the TRH content was reduced in the spinal cord
(50%) and medulla (20%) (Table I). However, TRH depletion was never as great as
serotonin depletion (>90%), nor was any change in TRH content measured in the
hypothalamus or midbrain. Thus far the identity of extrahypothalamic TRH has been
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somewhat controversial, hence we proceeded to ascertain that, indeed, the TRH
immunoactivity in these tissues co-chromatographs with synthetic TRH using reverse-phase
HPLC separation31 (data not shown)
In contrast, substance P content of the dorsal or ventral spinal cord, medulla, midbrain and
hypothalamus was not altered by the neonatal 5,7-DHT treatment (Table II). These findings
are somewhat surprising, in view of reports12,24,30 indicating that adult 5,7-DHT treatment
results in a substantial loss of substance P in the ventral spinal cord To examine this issue
further, we also have replicated the effect of adult 5,7-DHT treatment (day 32) on spinal
cord substance P Two weeks after treatment, the ventral spinal cord substance P had
declined by 50%, while dorsal spinal cord substance P remained unchanged.
To determine if the substance P in afferent nerve terminals was influencing our results, we
treated rats neonatally with capsaicin19,37 Capsaicin treatment alone led to an 85% decrease
of substance P content in the spinal cord. When capsaicin was given in conjunction with 5,7-
DHT, no additional loss of substance P was measured in the medulla or spinal cord.
Capsaicin alone or in conjunction with 5,7-DHT did not lead to any additional changes in
TRH content of any brain region.
Immunocytochemistry
Fixation constituted a crucial factor for effective visualization of TRH, substance P or
serotonin. To demonstrate TRH-IR with our antiserum, the tissue must be fixed with
acrolein23, while serotonin could be detected only in tissue fixed with formaldehyde. The
serotonin antisera apparently binds to 6-OH-tetrahydro-β-carbohne, a reaction product of
formaldehyde and serotonin. Unlike Hokfelt et al.13,14, we have not been able to
demonstrate any TRH-IR in tissues fixed with paraformaldehyde. Fortunately, both acrolein
and paraformaldehyde were suitable fixatives for immunocytochemical localization of
substance P.
The effect of 5,7-DHT on serotonin lmmunostaining in neurons of the rat ventral medulla is
shown in Fig. 1. Following the neonatal treatment, the number of serotonergic neurons and
terminals is dramatically reduced throughout the entire brain35.
Although TRH was only demonstrated in acrolein-fixed tissue, the immunocytochemical
pattern of neuronal populations was virtually identical to that reported by Hokfelt et al.13,14
and Lechan and Jackson23. Numerous TRH-IR neurons and fibers were seen throughout the
pons-medulla. There is a correlation between substance P cell bodies (Fig. 2A) and the
location of TRH-positive cells in the ventral hindbrain (Fig. 2C). In addition, we have
observed many TRH-positive cells in the hypothalamus. No TRH-immunoreactive neurons
were observed in any other region, including the midbrain and the dorsal and medial raphe
nucleus. Following neonatal 5,7-DHT treatment, no intact TRH-IR neurons in the ventral
pons-medulla were observed. However, many TRH-IR nerve terminals remained present,
particularly in the solitary tract (Fig. 2D and E), and this is consistent with the observation
of relatively modest reductions in TRH content following 5,7-DHT treatment. The density
of TRH fibers was significantly decreased in the ventral horn of the spinal cord as others
have previously demonstrated12. Hypothalamic TRH-IR did not appear to be altered
following 5,7-DHT treatment.
Substance P – IR was demonstrated in tissue fixed with either acrolein or paraformaldehyde
and its distribution appeared identical in tissue prepared with either fixatives. A much larger
number of substance P-IR neurons, in comparison to TRH neurons, were seen throughout
the brain. In the ventral medulla (Fig. 2A), substance P seems to be located in the same
neurons as TRH and serotonin20,32. However, we observed only a few substance P neurons
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in either the dorsal or medial raphe nucleus. Following neonatal 5,7-DHT treatment,
substance P immunoreactivity in neurons of the ventral pons-medulla was completely
eliminated (Fig. 2B). Substance P – IR cell groups in other brain regions, such as
interpeduncular nucleus, habenula and dorsal pons-medulla, were not affected by the
neurotoxin treatment. A group of substance P – IR neurons located slightly lateral to the
dorsal raphe nucleus was not eliminated. Following this early treatment, we did not notice
any region with significant nerve terminal loss, although given the high density of substance
P terminals throughout the brain, it would be difficult to observe any small change.
Discussion
In a previous paper we have characterized the extensive destruction of brain serotonergic
neurons, following early neonatal 5,7-DHT treatment35. Such treatment results in the cell
death of more than 85% of serotonergic neurons, yet catecholamine neurons remain
undamaged. Other investigators have demonstrated that treatment of adult rats or the
subcutaneous treatment of neonatal rats results in pruning of distal terminals without loss of
proximal fibers and serotonergic cell bodies2, reviewed in ref. 4. Since these cell bodies
remain intact within the pons-medulla and midbrain, it has not been possible to interpret
unambiguously thus far the effect of serotonin depletion on putative peptide content or its
co-localization in these brain regions. On the other hand, as serotonergic neurons do
degenerate following neonatal 5,7-DHT treatment, it seems unlikely that the surviving
peptide neurons contain serotonin. Hence, our 5,7-DHT treatment paradigm may provide
biochemical and immunocytochemical data for determination of the relative contribution of
co-localized peptide content to the total peptide concentration.
TRH-serotonin co-localization
The present investigation has demonstrated that neonatal 5,7-DHT treatment results in
concurrent destruction of certain neuronal populations which contain serotonin, TRH and
substance P. Importantly, this study has provided evidence indicating that the amount of
either peptide which is co-localized with serotonin constitutes a relatively small portion,
compared to the amount of peptide that is not co-localized. The ventral spinal cord appears
to be the only brain region where a significant degree of co-localization exists. TRH content
declines by 50%, following 5,7-DHT, indicating that at least half the amount of this peptide
must be co-localized with serotonin. However, the degree of co-localization is only 20% in
the pons-medulla, and in rostral brain areas, TRH does not appear to be significantly co-
localized with serotonin. These findings are consistent with the loss of TRH-IR in the
ventral spinal cord, although some TRH fibers remain intact, particularly dorsal to the spinal
canal. The modest effect of the neurotoxin on medullary TRH content is consistent with the
presence of many TRH-IR terminals throughout the hindbrain. In general, as detected by our
technique, there are few remaining TRH-IR cells in any CNS region, with the exception of
the hypothalamus, raising the possibility that the TRH-IR terminals may either be of
hypothalamic origin or alternatively they may enter the brain from peripheral sensory
ganglia. In either case, it seems clear from these data that a major portion of TRH is not co-
localized with serotonin, and TRH which is co-localized must arise entirely from
serotonergic neurons of the pons-medulla and not midbrain.
Substance P–serotonin co-localization
The co-localization of serotonin and substance P appears to be more complex, since the
serotonin neurons of the ventral pons-medulla are destroyed, yet substance P content is not
decreased following the neurotoxin. Presumably the co-localized substance P represents
such a small portion of the total substance P content that the effect of 5,7-DHT could not be
reliably determined. Most substance P-containing neurons are in brain regions which do not
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contain serotonergic neurons15,26, and they appear to be unaffected by the neonatal 5,7-DHT
treatment. As in the case of TRH co-localization, cells of the ventral pons-medulla are the
only serotonergic neurons which also seem to contain substance P. We have not observed
any evidence for substance P in serotonergic cells of the dorsal or medial raphe nucleus or in
terminals projecting rostrally. Previously, Chan-Palay9 observed that treatment of adult rats
with 5,6-dihydroxytryptamine led to the loss of serotonin–substance P cells in the ventral
medulla. Unlike our study, the potential for damage to catecholamine neurons was present,
since animals were not pretreated with the catecholamine uptake inhibitor, desipramine
Further, our data have provided additional evidence for taxonomic separation of
serotonergic neurons in the midbrain and pons-medulla on the basis of peptide content.
Midbrain serotonergic neurons (including the DRN and MRN) do not appear to contain any
detectable amount of substance P or TRH. Conversely, the serotonin neurotoxin appears to
have no effect on any substance P or TRH neurons anterior to the pons. In contrast, all
neurons in the ventral pons-medulla which evidently co-localize substance P, TRH and
serotonin, are susceptible to 5,7-DHT, indicating that these neurons probably share some
common phenotypic characteristics. Olson and Seiger28 and Wallace et al.36 reported the
differential origin of medullary and midbrain serotonergic neurons from two separate
precursor zones The B1–B3 cell groups arise from the embryonic medulla on embryonic day
14, whereas midbrain cells arise nearly 2 days later from a region rostral to the pontine
flexure. Differences of developmental timing and origin are likely to lead to the selective
distribution of peptides in neurons which contain serotonin.
The effect of 5,7-DHT treatment in adult rats on substance P and TRH
immunocytochemistry and content was recently described by Gilbert et al 12 These
investigators reported that there was a concomitant decline in serotonin and both peptides in
the ventral spinal cord. However, we have not observed a parallel between serotonin
depletion and substance P or TRH content in the spinal cord or any other brain tissue,
following neonatal 5,7-DHT treatment. Tessler et al.33 have demonstrated substance P
recovery in the cat, following unilateral spinal deafferentation, thus raising the possibility of
reinnervation of depleted regions.
Alternatively, one may be measuring different peptides with the different antisera used in
these studies. The monoclonal substance P antibody has been well characterized by Cuello
et al.10 and its appears to be specific for the carboxyl terminus of the peptides. However,
substance P assays using this antibody give peptide concentration values which are less than
those determined with assays based on polyclonal substance P antisera10
Neonatal 5,7-DHT treatment has provided a method for eliminating virtually all medullary
serotonergic neurons, including those that co-store substance P and TRH. Although we have
found modest changes of peptide distribution and content in the medulla, we have also
observed apparent long-term supersensitivity to exogenously applied peptides Respiratory
responses to intracisternal TRH in halo-thane-anesthetized rats are significantly enhanced,
following neonatal 5,7-DHT treatment27. Moreover, in depleted animals, the [125I]TRH
binding is greater in the spinal cord and medulla, but not in the hypothalamus29.
Taken together, these different lines of evidence indicate that the neonatal 5,7-DHT
paradigm can serve as a useful model system for the study of co-localization of serotonin
and peptide neurotransmitters and for an elucidation of the functional significance of this
phenomenon
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Serotonin immunocytochemistry in the rat ventral medulla A: control B: neonatal 5,7-DHT
+ DMI Bar = 100 μm.
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A substance P immunoreactivity in the medulla of control rat. B: substance P
immunoreactivity in medulla of 5,7-DHT-treated rat. C: TRH-immunoreactivc cells in the
medulla D TRH immunoreactivity in control rat. E TRH immunoreactivity in 5,7-DHT-
treated rat. Bar = 100 μm. ap, area postrema; cc. central canal: NTS. nucleus tractus solitaris
A and B were counterstained with toluidine blue, and D and E were photographed using
dark-field illumination
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TABLE I
TRH content of several brain regions following neonatal 5,7-DHT + DMI and/or capsaicin
treatment
Rats were treated as described in Materials and Methods n = 12 Data expressed as X̄ ± SEM
Treatment Spinal cord Pons-medulla (ng/mg protein) Midbrain
Saline 0 98 ± 0 15 0.41 ± 0 08 0 24 ± 0 04
5,7-DHT + DMI 0 43 ± 0 11* 0 25 ± 0 05* 0 20 ± 0 05
Capsaicin 0 85 ± 0 12 0 47 ± 0 05 0 29 ± 0 03
5,7-DHT + DMI + capsaicin 0 45 ± 0 08* 0 27 ± 0 04* 0 31 ± 0 06
*
P < 0 05 when compared to saline
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TABLE II
Substance P content of several brain regions following neonatal 5,7-DHT + DMI and/or
capsaicin treatment
Rats were treated as described in Materials and Methods n = 12 Data expressed asX̄ + SEM
Treatment Spinal cord Pons-medulla (ng/mg protein) Midbrain
Saline 7 70 ± 1 05 0 86 ± 0 11 0 71 ± 0 09
5,7-DHT + DMI 8 40 ± 0 81 0 76 ± 0 09 0 79 ± 0 15
Capsaicin 1 15 ± 0 25* 0 60 ± 0 04* 0 84 ± 0 06
5,7-DHT + DMI + capsaicin 1 27 ± 0 17* 0 64 ± 0 05* 0 73 ± 0 08
*
P < 0 05 when compared to control
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